---
title: "Pfizer: Business Model & Revenue Engine"
description: "Pfizer revenue by region from its fiscal 2025 Form 10-K, with each part's share, growth and profitability explained. 59% of revenue came from the United States."
canonical: https://www.getswoopr.com/stocks/companies/pfizer/business-model/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Pfizer: Business Model & Revenue Engine

## Direct Answer

Pfizer reports revenue across 3 geographic regions in its fiscal 2025 Form 10-K. United States is the largest, with $37.1 billion of revenue (59% of the total), followed by International Developed Markets at $16.2 billion (26%). 59% of revenue came from the United States.

## How Does Pfizer Make Money?

No single region supplies a majority of revenue: the largest, United States, is 59%, which spreads Pfizer's exposure across several demand drivers. Between fiscal 2024 and 2025, International Emerging Markets grew fastest (+4.9%) and United States slowest (-4.2%), so the revenue mix tilts toward International Emerging Markets while that gap lasts.

| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| United States | $37.1 billion | $38.7 billion | 59.2% | -4.2% |
| International Developed Markets | $16.2 billion | $16.1 billion | 25.9% | 0.8% |
| International Emerging Markets | $9.3 billion | $8.9 billion | 14.9% | 4.9% |

![Bar chart of Pfizer revenue by region for fiscal 2025: United States 59.2%, International Developed Markets 25.9%, International Emerging Markets 14.9%.](https://www.getswoopr.com/images/charts/pfizer-business-model-segment-mix.webp)
*Pfizer revenue by region as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.*

## What the Segment Figures Do Not Show

The rows above add up to 100% of Pfizer's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.

## Where These Numbers Come From

Every figure on this page is a value Pfizer reported in the segment note and revenue disclosures of its Form 10-K filed February 26, 2026 (accession 0000078003-26-000026), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.

Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.

## Frequently Asked Questions

### What are Pfizer's main regions?

In its fiscal 2025 Form 10-K, Pfizer reports revenue for United States, International Developed Markets and International Emerging Markets.

### Which part of Pfizer brings in the most revenue?

United States, with $37.1 billion of revenue in fiscal 2025, or 59% of the total.

### How much of Pfizer's revenue comes from outside the United States?

41% in fiscal 2025, by the geographic breakdown Pfizer reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.

## References

- [SEC EDGAR: PFIZER INC Form 10-K filed February 26, 2026](https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm)
- [SEC EDGAR: PFIZER INC annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=78003&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)
- [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets)

## Related Pages

- [Pfizer company dossier](https://www.getswoopr.com/stocks/companies/pfizer/)
- [Pfizer financial metrics](https://www.getswoopr.com/stocks/companies/pfizer/metrics/)
- [Pfizer financial risk indicators](https://www.getswoopr.com/stocks/companies/pfizer/risks/)
- [Pfizer peer comparison](https://www.getswoopr.com/stocks/companies/pfizer/competitors/)
- [Pfizer business model and revenue mix](https://www.getswoopr.com/stocks/companies/pfizer/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).